APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Asthma Short Acting Beta Agonists

Compare research editions
View pricing & licenses

Selected research

Industry Research

Anti-Asthma Short Acting Beta Agonists Industry Research Report 2026

23 December 2025124 pages

Choose your research edition.

Industry ResearchAnti-Asthma Short Acting Beta Agonists Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Asthma Short Acting Beta Agonists Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Anti-Asthma Short Acting Beta Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Asthma Short Acting Beta Agonists Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Asthma Short Acting Beta Agonists Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Anti-Asthma Short Acting Beta Agonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Anti-Asthma Short Acting Beta Agonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Anti-Asthma Short Acting Beta Agonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Anti-Asthma Short Acting Beta Agonists include Chia Tai Tianqing Pharmaceutical Group, Teva Pharmaceutical, Sichuan Puretech Pharmaceutical, Sanofi, Novartis, Shandong Lunan Pharmaceutical, Joincare Pharmaceutical Group Industry, Pfizer and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Anti-Asthma Short Acting Beta Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Anti-Asthma Short Acting Beta Agonists Market by Company

Chia Tai Tianqing Pharmaceutical Group

Teva Pharmaceutical

Sichuan Puretech Pharmaceutical

Sanofi

Novartis

Shandong Lunan Pharmaceutical

Joincare Pharmaceutical Group Industry

Pfizer

Jiangsu Hengrui Pharmaceuticals

GlaxoSmithKline

AstraZeneca

Viatris

Boehringer Ingelheim

Anti-Asthma Short Acting Beta Agonists Segment by Type

Non-Selective Beta Receptor Agonists

Selective Beta 2 Receptor Agonists

Anti-Asthma Short Acting Beta Agonists Segment by Application

Pharmacy

Hospital

Clinic

Others

Anti-Asthma Short Acting Beta Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Asthma Short Acting Beta Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Asthma Short Acting Beta Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Asthma Short Acting Beta Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Anti-Asthma Short Acting Beta Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Anti-Asthma Short Acting Beta Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Anti-Asthma Short Acting Beta Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Anti-Asthma Short Acting Beta Agonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Anti-Asthma Short Acting Beta Agonists Sales (units) of Manufacturers (2021-2026) Table 7. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global Anti-Asthma Short Acting Beta Agonists Revenue of Manufacturers (2021-2026) Table 9. Global Anti-Asthma Short Acting Beta Agonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Anti-Asthma Short Acting Beta Agonists Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Anti-Asthma Short Acting Beta Agonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Anti-Asthma Short Acting Beta Agonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Anti-Asthma Short Acting Beta Agonists, Product Type & Application Table 14. Global Anti-Asthma Short Acting Beta Agonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Anti-Asthma Short Acting Beta Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chia Tai Tianqing Pharmaceutical Group Company Information Table 19. Chia Tai Tianqing Pharmaceutical Group Business Overview Table 20. Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 22. Chia Tai Tianqing Pharmaceutical Group Recent Developments Table 23. Teva Pharmaceutical Company Information Table 24. Teva Pharmaceutical Business Overview Table 25. Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 27. Teva Pharmaceutical Recent Developments Table 28. Sichuan Puretech Pharmaceutical Company Information Table 29. Sichuan Puretech Pharmaceutical Business Overview Table 30. Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 32. Sichuan Puretech Pharmaceutical Recent Developments Table 33. Sanofi Company Information Table 34. Sanofi Business Overview Table 35. Sanofi Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Sanofi Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 37. Sanofi Recent Developments Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Novartis Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 42. Novartis Recent Developments Table 43. Shandong Lunan Pharmaceutical Company Information Table 44. Shandong Lunan Pharmaceutical Business Overview Table 45. Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 47. Shandong Lunan Pharmaceutical Recent Developments Table 48. Joincare Pharmaceutical Group Industry Company Information Table 49. Joincare Pharmaceutical Group Industry Business Overview Table 50. Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 52. Joincare Pharmaceutical Group Industry Recent Developments Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Pfizer Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 57. Pfizer Recent Developments Table 58. Jiangsu Hengrui Pharmaceuticals Company Information Table 59. Jiangsu Hengrui Pharmaceuticals Business Overview Table 60. Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 62. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 63. GlaxoSmithKline Company Information Table 64. GlaxoSmithKline Business Overview Table 65. GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 67. GlaxoSmithKline Recent Developments Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. AstraZeneca Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 72. AstraZeneca Recent Developments Table 73. Viatris Company Information Table 74. Viatris Business Overview Table 75. Viatris Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Viatris Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 77. Viatris Recent Developments Table 78. Boehringer Ingelheim Company Information Table 79. Boehringer Ingelheim Business Overview Table 80. Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Product Portfolio Table 82. Boehringer Ingelheim Recent Developments Table 83. Global Anti-Asthma Short Acting Beta Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2021-2026) & (units) Table 85. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Region (2021-2026) Table 86. Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2027-2032) & (units) Table 87. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Region (2027-2032) Table 88. Global Anti-Asthma Short Acting Beta Agonists Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Region (2021-2026) Table 90. Global Anti-Asthma Short Acting Beta Agonists Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Region (2027-2032) Table 92. North America Anti-Asthma Short Acting Beta Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2026) & (units) Table 94. North America Anti-Asthma Short Acting Beta Agonists Sales by Country (2027-2032) & (units) Table 95. North America Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Anti-Asthma Short Acting Beta Agonists Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Anti-Asthma Short Acting Beta Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2026) & (units) Table 99. Europe Anti-Asthma Short Acting Beta Agonists Sales by Country (2027-2032) & (units) Table 100. Europe Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Anti-Asthma Short Acting Beta Agonists Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Anti-Asthma Short Acting Beta Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2026) & (units) Table 104. Asia Pacific Anti-Asthma Short Acting Beta Agonists Sales by Country (2027-2032) & (units) Table 105. Asia Pacific Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Anti-Asthma Short Acting Beta Agonists Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Anti-Asthma Short Acting Beta Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2026) & (units) Table 109. South America Anti-Asthma Short Acting Beta Agonists Sales by Country (2027-2032) & (units) Table 110. South America Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Anti-Asthma Short Acting Beta Agonists Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2026) & (units) Table 114. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Sales by Country (2027-2032) & (units) Table 115. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Anti-Asthma Short Acting Beta Agonists Sales by Type (2021-2026) & (units) Table 118. Global Anti-Asthma Short Acting Beta Agonists Sales by Type (2027-2032) & (units) Table 119. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Type (2021-2026) Table 120. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Type (2027-2032) Table 121. Global Anti-Asthma Short Acting Beta Agonists Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Anti-Asthma Short Acting Beta Agonists Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Type (2021-2026) Table 124. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Type (2027-2032) Table 125. Global Anti-Asthma Short Acting Beta Agonists Price by Type (2021-2026) & (USD/unit) Table 126. Global Anti-Asthma Short Acting Beta Agonists Price by Type (2027-2032) & (USD/unit) Table 127. Global Anti-Asthma Short Acting Beta Agonists Sales by Application (2021-2026) & (units) Table 128. Global Anti-Asthma Short Acting Beta Agonists Sales by Application (2027-2032) & (units) Table 129. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Application (2021-2026) Table 130. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Application (2027-2032) Table 131. Global Anti-Asthma Short Acting Beta Agonists Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Anti-Asthma Short Acting Beta Agonists Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Application (2021-2026) Table 134. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Application (2027-2032) Table 135. Global Anti-Asthma Short Acting Beta Agonists Price by Application (2021-2026) & (USD/unit) Table 136. Global Anti-Asthma Short Acting Beta Agonists Price by Application (2027-2032) & (USD/unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Anti-Asthma Short Acting Beta Agonists Distributors List Table 140. Anti-Asthma Short Acting Beta Agonists Customers List Table 141. Anti-Asthma Short Acting Beta Agonists Industry Trends Table 142. Anti-Asthma Short Acting Beta Agonists Industry Drivers Table 143. Anti-Asthma Short Acting Beta Agonists Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Anti-Asthma Short Acting Beta Agonists Product Image Figure 5. Global Anti-Asthma Short Acting Beta Agonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Anti-Asthma Short Acting Beta Agonists Market Size (2021-2032) & (US$ Million) Figure 7. Global Anti-Asthma Short Acting Beta Agonists Sales (2021-2032) & (units) Figure 8. Global Anti-Asthma Short Acting Beta Agonists Average Price (USD/unit) & (2021-2032) Figure 9. Non-Selective Beta Receptor Agonists Product Image Figure 10. Selective Beta 2 Receptor Agonists Product Image Figure 11. Pharmacy Product Image Figure 12. Hospital Product Image Figure 13. Clinic Product Image Figure 14. Others Product Image Figure 15. Global Anti-Asthma Short Acting Beta Agonists Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Anti-Asthma Short Acting Beta Agonists, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Anti-Asthma Short Acting Beta Agonists Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Anti-Asthma Short Acting Beta Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Anti-Asthma Short Acting Beta Agonists Sales by Region in 2025 Figure 21. Global Anti-Asthma Short Acting Beta Agonists Revenue by Region in 2025 Figure 22. North America Anti-Asthma Short Acting Beta Agonists Market Size by Country in 2025 Figure 23. North America Anti-Asthma Short Acting Beta Agonists Sales Market Share by Country (2021-2032) Figure 24. North America Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Country (2021-2032) Figure 25. United States Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Anti-Asthma Short Acting Beta Agonists Market Size by Country in 2025 Figure 29. Europe Anti-Asthma Short Acting Beta Agonists Sales Market Share by Country (2021-2032) Figure 30. Europe Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Country (2021-2032) Figure 31. Germany Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Anti-Asthma Short Acting Beta Agonists Market Size by Country in 2025 Figure 42. Asia Pacific Anti-Asthma Short Acting Beta Agonists Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Country (2021-2032) Figure 44. China Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Anti-Asthma Short Acting Beta Agonists Market Size by Country in 2025 Figure 53. South America Anti-Asthma Short Acting Beta Agonists Sales Market Share by Country (2021-2032) Figure 54. South America Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Country (2021-2032) Figure 55. Brazil Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Market Size by Country in 2025 Figure 59. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Country (2021-2032) Figure 61. Egypt Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Anti-Asthma Short Acting Beta Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Type (2021-2032) Figure 67. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Type (2021-2032) Figure 68. Global Anti-Asthma Short Acting Beta Agonists Price (USD/unit) by Type (2021-2032) Figure 69. Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Application (2021-2032) Figure 70. Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Application (2021-2032) Figure 71. Global Anti-Asthma Short Acting Beta Agonists Price (USD/unit) by Application (2021-2032) Figure 72. Anti-Asthma Short Acting Beta Agonists Value Chain Figure 73. Anti-Asthma Short Acting Beta Agonists Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Anti-Asthma Short Acting Beta Agonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • Non-Selective Beta Receptor Agonists
  • Selective Beta 2 Receptor Agonists
Applications
  • Pharmacy
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chia Tai Tianqing Pharmaceutical Group
  • Teva Pharmaceutical
  • Sichuan Puretech Pharmaceutical
  • Sanofi
  • Novartis
  • Shandong Lunan Pharmaceutical
  • Joincare Pharmaceutical Group Industry
  • Pfizer
  • Jiangsu Hengrui Pharmaceuticals
  • GlaxoSmithKline
  • AstraZeneca
  • Viatris
  • Boehringer Ingelheim

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Anti-Asthma Short Acting Beta Agonists Market Size (2021-2032)
  4. 2.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales (2021-2032)
  5. 2.2.3 Global Anti-Asthma Short Acting Beta Agonists Market Average Price (2021-2032)
  6. 2.3 Anti-Asthma Short Acting Beta Agonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Non-Selective Beta Receptor Agonists
  9. 2.3.3 Selective Beta 2 Receptor Agonists
  10. 2.4 Anti-Asthma Short Acting Beta Agonists by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Pharmacy
  13. 2.4.3 Hospital
  14. 2.4.4 Clinic
  15. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Anti-Asthma Short Acting Beta Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Anti-Asthma Short Acting Beta Agonists Sales (units) of Manufacturers (2021-2026)
  3. 3.3 Global Anti-Asthma Short Acting Beta Agonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Anti-Asthma Short Acting Beta Agonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Anti-Asthma Short Acting Beta Agonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Anti-Asthma Short Acting Beta Agonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Anti-Asthma Short Acting Beta Agonists, Product Type & Application
  8. 3.8 Global Manufacturers of Anti-Asthma Short Acting Beta Agonists, Established Date
  9. 3.9 Global Anti-Asthma Short Acting Beta Agonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chia Tai Tianqing Pharmaceutical Group
  2. 4.1.1 Chia Tai Tianqing Pharmaceutical Group Company Information
  3. 4.1.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
  4. 4.1.3 Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Product Portfolio
  6. 4.1.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments
  7. 4.2 Teva Pharmaceutical
  8. 4.2.1 Teva Pharmaceutical Company Information
  9. 4.2.2 Teva Pharmaceutical Business Overview
  10. 4.2.3 Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
  12. 4.2.5 Teva Pharmaceutical Recent Developments
  13. 4.3 Sichuan Puretech Pharmaceutical
  14. 4.3.1 Sichuan Puretech Pharmaceutical Company Information
  15. 4.3.2 Sichuan Puretech Pharmaceutical Business Overview
  16. 4.3.3 Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
  18. 4.3.5 Sichuan Puretech Pharmaceutical Recent Developments
  19. 4.4 Sanofi
  20. 4.4.1 Sanofi Company Information
  21. 4.4.2 Sanofi Business Overview
  22. 4.4.3 Sanofi Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Sanofi Anti-Asthma Short Acting Beta Agonists Product Portfolio
  24. 4.4.5 Sanofi Recent Developments
  25. 4.5 Novartis
  26. 4.5.1 Novartis Company Information
  27. 4.5.2 Novartis Business Overview
  28. 4.5.3 Novartis Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis Anti-Asthma Short Acting Beta Agonists Product Portfolio
  30. 4.5.5 Novartis Recent Developments
  31. 4.6 Shandong Lunan Pharmaceutical
  32. 4.6.1 Shandong Lunan Pharmaceutical Company Information
  33. 4.6.2 Shandong Lunan Pharmaceutical Business Overview
  34. 4.6.3 Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
  36. 4.6.5 Shandong Lunan Pharmaceutical Recent Developments
  37. 4.7 Joincare Pharmaceutical Group Industry
  38. 4.7.1 Joincare Pharmaceutical Group Industry Company Information
  39. 4.7.2 Joincare Pharmaceutical Group Industry Business Overview
  40. 4.7.3 Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Product Portfolio
  42. 4.7.5 Joincare Pharmaceutical Group Industry Recent Developments
  43. 4.8 Pfizer
  44. 4.8.1 Pfizer Company Information
  45. 4.8.2 Pfizer Business Overview
  46. 4.8.3 Pfizer Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Pfizer Anti-Asthma Short Acting Beta Agonists Product Portfolio
  48. 4.8.5 Pfizer Recent Developments
  49. 4.9 Jiangsu Hengrui Pharmaceuticals
  50. 4.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 4.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 4.9.3 Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Product Portfolio
  54. 4.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 4.10 GlaxoSmithKline
  56. 4.10.1 GlaxoSmithKline Company Information
  57. 4.10.2 GlaxoSmithKline Business Overview
  58. 4.10.3 GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Product Portfolio
  60. 4.10.5 GlaxoSmithKline Recent Developments
  61. 4.11 AstraZeneca
  62. 4.11.1 AstraZeneca Company Information
  63. 4.11.2 AstraZeneca Business Overview
  64. 4.11.3 AstraZeneca Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 AstraZeneca Anti-Asthma Short Acting Beta Agonists Product Portfolio
  66. 4.11.5 AstraZeneca Recent Developments
  67. 4.12 Viatris
  68. 4.12.1 Viatris Company Information
  69. 4.12.2 Viatris Business Overview
  70. 4.12.3 Viatris Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Viatris Anti-Asthma Short Acting Beta Agonists Product Portfolio
  72. 4.12.5 Viatris Recent Developments
  73. 4.13 Boehringer Ingelheim
  74. 4.13.1 Boehringer Ingelheim Company Information
  75. 4.13.2 Boehringer Ingelheim Business Overview
  76. 4.13.3 Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Product Portfolio
  78. 4.13.5 Boehringer Ingelheim Recent Developments
5 Global Anti-Asthma Short Acting Beta Agonists Market Scenario by Region
  1. 5.1 Global Anti-Asthma Short Acting Beta Agonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2021-2032
  3. 5.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2021-2026
  4. 5.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2027-2032
  5. 5.3 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region: 2021-2032
  6. 5.3.1 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region: 2021-2026
  7. 5.3.2 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region: 2027-2032
  8. 5.4 North America Anti-Asthma Short Acting Beta Agonists Market Facts & Figures by Country
  9. 5.4.1 North America Anti-Asthma Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
  11. 5.4.3 North America Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Anti-Asthma Short Acting Beta Agonists Market Facts & Figures by Country
  16. 5.5.1 Europe Anti-Asthma Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
  18. 5.5.3 Europe Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Anti-Asthma Short Acting Beta Agonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Anti-Asthma Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Anti-Asthma Short Acting Beta Agonists Market Facts & Figures by Country
  41. 5.7.1 South America Anti-Asthma Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
  43. 5.7.3 South America Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Anti-Asthma Short Acting Beta Agonists Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Anti-Asthma Short Acting Beta Agonists Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Anti-Asthma Short Acting Beta Agonists Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Type (2021-2032)
  2. 6.1.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Type (2021-2032) & (units)
  3. 6.1.2 Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global Anti-Asthma Short Acting Beta Agonists Revenue by Type (2021-2032)
  5. 6.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Anti-Asthma Short Acting Beta Agonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Application (2021-2032)
  2. 7.1.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Application (2021-2032) & (units)
  3. 7.1.2 Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global Anti-Asthma Short Acting Beta Agonists Revenue by Application (2021-2032)
  5. 7.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Anti-Asthma Short Acting Beta Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Anti-Asthma Short Acting Beta Agonists Value Chain Analysis
  2. 8.1.1 Anti-Asthma Short Acting Beta Agonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Anti-Asthma Short Acting Beta Agonists Production Mode & Process
  5. 8.2 Anti-Asthma Short Acting Beta Agonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Anti-Asthma Short Acting Beta Agonists Distributors
  8. 8.2.3 Anti-Asthma Short Acting Beta Agonists Customers
9 Global Anti-Asthma Short Acting Beta Agonists Analyzing Market Dynamics
  1. 9.1 Anti-Asthma Short Acting Beta Agonists Industry Trends
  2. 9.2 Anti-Asthma Short Acting Beta Agonists Industry Drivers
  3. 9.3 Anti-Asthma Short Acting Beta Agonists Industry Opportunities and Challenges
  4. 9.4 Anti-Asthma Short Acting Beta Agonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst